Participation to Lyon Pole Bourse


Press launch        Ecully, September 22, 2022 -18h

Spineway participates to the Lyon Pôle Bourse Forum

SPINEWAY, specialised within the design, manufacturing and advertising and marketing of backbone implants and surgical devices, publicizes its participation to the Lyon Pôle Bourse Regional Values Forum, on Wednesday, September 28, 2022, on the Palais de la Bourse de Lyon, Esplanade François Mitterrand, in Lyon.
This investor discussion board devoted to listed corporations based mostly within the Auvergne-Rhône-Alpes and Bourgogne-Franche-Comté areas, will probably be a possibility for Spineway to meet buyers and monetary analysts by means of “one-to-one” or “one-to-few” conferences, both face-to-face or by way of videoconference.
The Lyon Regional Stock Exchange Forum brings collectively greater than 100 skilled buyers with the managers of some thirty giant, mid and small caps. The 2021 version of the discussion board has enabled 550 wealthy and fruitful conferences.

Next Appointment :
October 14, 2022: third quarter revenues

Find all of the details about Spineway on

Ce communiqué de presse est rédigé en anglais et en français. En cas de divergence, la model française prévaudra.

Spineway designs, manufactures and markets progressive surgical implants and ancillary merchandise (devices) for the remedy of extreme backbone pathologies.
Spineway has a worldwide community of greater than 50 impartial distributors and generates 90% of its revenues from exports.
Spineway, eligible for FCPI funds, has obtained the OSEO Excellence label since 2011 and is a winner of the Deloitte Fast 50 trophy (2011). INPI Rhône Alpes Patent Policy Award (2013) – INPI Talent Label (2015).
ISIN : FR001400BVK2– ALSPW        

See also  Scientists from Spain and India Lead an International Project to Develop New Antibiotics Against Gram-Negative Bacteria

Contacts :


Shareholder Line
Open Tuesday to Thursday (10am-12pm)
0806 70 60 60

Eligible PEA / PME


Euronext Growth


Finance & Communication

Investor Relations
Solène Kennis

Source link


Please enter your comment!
Please enter your name here